Overview and Pediatric Differences
Pediatric Inflammatory Bowel Disease (IBD)—comprising Crohn Disease (CD), Ulcerative Colitis (UC), and IBD-Unclassified (IBD-U)—exhibits distinct phenotypic differences compared to adult disease. Children present with more extensive pan-enteric involvement, higher rates of stricturing/penetrating complications, and unique pediatric consequences including growth impairment, delayed puberty, and severe osteopenia.
Classification follows the Paris Classification (pediatric modification of Montreal), which incorporates age at diagnosis ($A1a < 10\text{ yr}$, $A1b\ 10–17\text{ yr}$) and explicitly tracks growth failure ($G0$ vs. $G1$).
The "Treat-to-Target" Strategy (STRIDE-II Consensus)
The Selecting Therapeutic Targets in Inflammatory Bowel Disease-II (STRIDE-II, pediatric update) established formal treatment targets to alter long-term disease course:
flowchart TD
A["Pediatric IBD Diagnosed & Staged (Paris Classification)"] --> B["Induction of Remission:<br/>EEN for 6–8 weeks in luminal CD OR Corticosteroids / Biologics"]
B --> C["Short-Term Target (Weeks 2–4):<br/>Clinical Response & Symptom Resolution<br/>(PCDAI < 10 or PUCAI < 10)"]
C --> D["Intermediate Target (Weeks 8–12):<br/>Biochemical Remission<br/>Normal CRP + Normalization of Fecal Calprotectin (< 100–250 μg/g)"]
D --> E["Long-Term Target (Months 6–12):<br/>1. Endoscopic Mucosal Healing (SES-CD = 0 or Mayo Score 0)<br/>2. Normalization of Linear Growth Velocity & Pubertal Staging<br/>3. Restoration of Normal Quality of Life (QoL)"]
E -->|Target Achieved| F["Maintenance with TDM-guided Biologics / Immunomodulators"]
E -->|Target Not Achieved| G["Dose Escalation via Proactive TDM OR Switch Biologic Class"]
| Timeframe | Target Category | Specific Objective Metrics |
|---|---|---|
| Immediate (Weeks 2–4) | Clinical Response | Reduction in Paediatric Crohn's Disease Activity Index (PCDAI) by $>12.5$ points, or Paediatric Ulcerative Colitis Activity Index (PUCAI) drop by $>20$ points. |
| Short-Term (Weeks 8–12) | Clinical & Biochemical Remission | Full clinical remission ($\text{PCDAI} < 10$, $\text{PUCAI} < 10$), normalization of serum albumin and CRP ($<5\text{ mg/L}$). |
| Intermediate (Months 3–6) | Biomarker Mucosal Remission | Fecal Calprotectin $< 100–250\ \mu\text{g/g}$ (surrogate non-invasive marker of gut healing). |
| Long-Term (Months 6–12) | Deep Mucosal & Histological Healing | Absence of ulcerations on ileocolonoscopy (SES-CD score $= 0$ or Mayo endoscopic subscore $0–1$); histological absence of neutrophils; restoration of normal linear growth velocity (height SDS recovery). |
Nutritional Induction Therapy: Exclusive Enteral Nutrition (EEN)
Clinical Protocol
- First-Line Induction: Recommended by ECCO and ESPGHAN as the primary first-line therapy for inducing remission in mild-to-moderate luminal pediatric Crohn Disease.
- Regimen: 100% of daily caloric and nutritional requirements administered via standard liquid polymeric formula (oral or via nasogastric tube) for 6 to 8 consecutive weeks, with total exclusion of all regular food products.
- Efficacy vs. Corticosteroids: Achieves clinical remission rates comparable to systemic oral corticosteroids ($75–85\%$), but demonstrates superior mucosal healing ($73\%$ vs. $33\%$) and enhances bone mineral density and linear growth without steroid-induced growth stunting.
- Maintenance Dietary Strategies: Crohn's Disease Exclusion Diet (CDED) combined with Partial Enteral Nutrition (PEN) maintains long-term remission while allowing structured reintroduction of specific whole foods.
Biologics and Advanced Targeted Therapies
flowchart LR
A["Biologic & Small-Molecule Arsenal"] --> B["Anti-TNF Agents<br/>• Infliximab (IV, TDM-guided)<br/>• Adalimumab (SC)"]
A --> C["Gut-Selective Anti-Integrin<br/>• Vedolizumab (anti-α4β7)"]
A --> D["Anti-IL-12/23 Pathway<br/>• Ustekinumab (anti-p40)<br/>• Risankizumab (anti-p19)"]
A --> E["Oral JAK Inhibitors<br/>• Upadacitinib (JAK-1 selective)<br/>• Tofacitinib"]
1. Anti-Tumor Necrosis Factor (Anti-TNF) Therapies
| Biologic Agent | Mechanism & Regimen | Indications & Pediatric Trial Evidence | Proactive Therapeutic Drug Monitoring (TDM) Targets |
|---|---|---|---|
| Infliximab (Remicade / Biosimilars) | Chimeric IgG1 monoclonal antibody against soluble and membrane-bound TNF-$\alpha$. IV infusion $5–10\text{ mg/kg}$ at 0, 2, and 6 weeks (induction), then every 8 weeks (maintenance). | Indicated for moderate-to-severe CD and UC refractory to first-line agents, or as "top-down" therapy for high-risk phenotypes (perianal fistulas, deep ulcerations, severe growth stunting). REACH Trial demonstrated $>88\%$ response at week 10. | Trough Level Optimization: • Maintenance trough: $> 5–10\ \mu\text{g/mL}$. • Perianal fistulizing CD: $> 10–15\ \mu\text{g/mL}$. • Detect Anti-Drug Antibodies (ADA); if high ADA present, switch drug class. |
| Adalimumab (Humira / Biosimilars) | Fully human IgG1 anti-TNF mAb. Subcutaneous injection every 2 weeks. Weight-tiered dosing: $80/40\text{ mg}$ or $160/80\text{ mg}$ induction, followed by $20–40\text{ mg}$ maintenance. | Indicated in children $\ge 2$ years. IMAgINE 1 Trial established efficacy in pediatric Crohn disease naive or intolerant to infliximab. | Maintenance trough concentration $> 7.5–10\ \mu\text{g/mL}$. |
2. Next-Generation Biologics and Small Molecules
| Drug | Mechanism of Action | Approved Indications & Advantages in Pediatrics |
|---|---|---|
| Vedolizumab (Entyvio) | Humanized mAb specifically antagonizing the $\alpha_4\beta_7$ integrin heterodimer, blocking mucosal addressin cell adhesion molecule-1 (MAdCAM-1) binding. | Gut-selective mechanism: Blocks T-lymphocyte trafficking into inflamed intestinal tissue without inducing systemic immunosuppression; low risk of opportunistic infections. Highly effective in pediatric UC and CD failing anti-TNF therapy. |
| Ustekinumab (Stelara) | Human IgG1 mAb binding the p40 subunit shared by IL-12 and IL-23, neutralizing Th1 and Th17 inflammatory pathways. | Given as weight-based IV loading followed by SC injections every 8–12 weeks. High efficacy in anti-TNF-refractory pediatric Crohn disease; low immunogenicity. |
| Oral JAK Inhibitors (Upadacitinib, Tofacitinib) | Oral small-molecule Janus Kinase inhibitors blocking intracellular cytokine signaling. | Rapid onset of action (days); highly effective for acute severe ulcerative colitis or anti-TNF refractory UC in older adolescents. |
Safety, Screening, and Monitoring Protocols
- Pre-Biologic Screening: Mandatory testing for latent tuberculosis (Tuberculin Skin Test / IGRA and Chest Radiography), Hepatitis B surface antigen/anti-HBc, Epstein-Barr Virus (EBV serology), Varicella zoster immunity, and baseline CBC/LFTs.
- Malignancy and Infection Risks: Infliximab co-administered with thiopurines (azathioprine) carries a rare but fatal risk of Hepatosplenic T-Cell Lymphoma (HSTCL), especially in young adolescent males. Current strategies favor anti-TNF monotherapy combined with proactive TDM optimization, avoiding prolonged combination therapy beyond 6–12 months.